Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this January/February 2022 edition, the focus is on an issue that has plagued the pharmaceutical industry for years: the incidence of protocol deviations and amendments in clinical trials. While these hurdles are both at new highs across all phases, they have been steadily increasing since the start of the COVID-19 pandemic.
From the results a new Tufts CSDD analysis conducted in 2020, some of the highlights in the report are:
The full report is available for purchase here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.